Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.69 USD | -0.62% | -3.95% | -20.76% |
Mar. 18 | Leerink Partners Adjusts Price Target on Walgreens Boots Alliance to $22 From $23, Maintains Market Perform Rating | MT |
Mar. 13 | Global markets live: Adidas, EON, Sandoz, Bayer, Boeing... |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.75 for the current year.
- The stock, which is currently worth 2024 to 0.18 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.76% | 17.95B | B- | ||
-16.37% | 12.62B | B | ||
-4.10% | 6.64B | C+ | ||
+1.97% | 5.79B | C | ||
+7.88% | 5B | D- | ||
-9.78% | 3.85B | B | ||
+9.51% | 3.7B | C- | ||
+25.52% | 3.64B | C | ||
-10.60% | 3.51B | C- | ||
+7.03% | 3.1B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Walgreens Boots Alliance, Inc. - Nasdaq
- Ratings Walgreens Boots Alliance, Inc.